Hepatic and lung methotrexate-associated polymorphic lymphoproliferative disorders arising during postoperative follow-up of renal cell carcinoma: a case report

Yoshi Miyamoto,Chihiro Kawasoe,Kaoru Ito,Nobuyuki Oguri,Takaya Murashima,Toyoharu Kamibeppu,Takahiro Nagai,Hiroki Takamori,Toshio Kamimura,Shoichiro Mukai,Yuichiro Sato,Toshiyuki Kamoto
DOI: https://doi.org/10.1186/s13256-023-04288-z
2023-12-22
Abstract:Introduction: Methotrexate induces lymphoproliferative disorders on rare occasions; however, its pathogenesis remains unknown. A clinical diagnosis based on imaging studies alone is often difficult. Case presentation: A 57-year-old Japanese woman was referred to our department for the evaluation of multiple lung and hepatic nodules that developed during methotrexate treatment for rheumatoid arthritis. Since she had a history of nephrectomy for localized renal cell carcinoma, multiple lung and hepatic metastases were initially considered. However, pathological diagnosis of the lung nodules (needle biopsy) revealed methotrexate-associated polymorphic-type lymphoproliferative disorders. After methotrexate discontinuation, continuous smooth shrinkage of the lung and liver lymphoproliferative disorders was observed. Conclusion: Methotrexate-associated lymphoproliferative disorders should be considered in the event of newly appearing neoplastic lesions, even during follow-up for renal cell carcinoma, if methotrexate is being administered.
What problem does this paper attempt to address?